Yondelis trabectedin: Phase II data

A Phase II trial in 98 heavily pretreated patients with relapsed ovarian cancer showed that 1.1 and 1.3 mg/m 2 Yondelis as monotherapy every 3 weeks produced an ORR of 28.6%, including 5 complete responses and 23 partial responses, plus 32 cases of stable disease. Additionally, Yondelis produced an ORR of 38.6% in platinum-sensitive patients (n=44), 26.1% in partially platinum-sensitive patients (n=23) and 16.1% for platinum-resistant patients (n=31). At a median follow-up of 8 months, median TTP was 5 months and median OS was 13 months. The trial enrolled patients with relapsed ovarian cancer who had received >=2 prior treatments. Data will be presented at the American Society of Clinical Oncology meeting in Chicago in June. ...